MNCs lead price cuts in China’s second round of centralized procurement

By Hongjiang Li, Staff Writer | Jan 23, 2020 | 1:20 AM GMT

MNC originators took the deepest price cuts in the second round of China’s expanded centralized procurement program for generic and off-patent drugs.

A list released Tuesday by China’s Joint Procurement Office showed that 77 winning bidders

Read the full 359 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE